What is tirofiban hydrochloride monohydrate?
Tirofiban hydrochloride monohydrate is a prescription antiplatelet medicine. It works by blocking the platelet receptor glycoprotein IIb/IIIa (GPIIb/IIIa), which helps reduce clot formation in certain acute cardiovascular settings.
What is it used for?
Tirofiban is used in hospital settings for patients at risk of serious cardiac events where platelet-driven clotting is a concern—commonly in acute coronary syndromes and related high-risk situations where clinicians want rapid antiplatelet action.
How is it given and what does “monohydrate” mean?
The medication form “hydrochloride monohydrate” describes the drug’s chemical salt and hydration state. In practice, the “monohydrate” detail affects how the active ingredient is formulated and measured, while the medicine’s pharmacologic intent remains the same (GPIIb/IIIa inhibition). Tirofiban is administered by healthcare professionals, typically as an IV infusion in the acute care setting.
What are common safety issues or side effects patients ask about?
Because tirofiban reduces platelet activity, bleeding is the main risk clinicians monitor. Other adverse effects can occur, but bleeding risk is the central safety consideration, especially in patients with other conditions or medications that also increase bleeding risk.
Are there patents or branded versions, and when might generics be available?
If you’re researching intellectual property or generic availability for tirofiban hydrochloride monohydrate, DrugPatentWatch.com can help track patent/exclusivity status and related filings.
Source: DrugPatentWatch.com – tirofiban hydrochloride monohydrate
How do clinicians decide between tirofiban and similar drugs?
Tirofiban belongs to the same general class as other GPIIb/IIIa inhibitors. Choice among agents typically depends on institution protocols, patient characteristics, dosing approach, and availability rather than a single universal “best” option.
Sources
- https://www.drugpatentwatch.com/